Integrated Report

Overview

The report outlines Sumitomo Dainippon Pharma's corporate strategy, financial performance, and sustainability initiatives for fiscal 2018 (ended March 31, 2019). The company established its Mid-term Business Plan 2022 and Vision 2033 to become a Global Specialized Player. It highlights progress in its core focus areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine/Cell Therapy. In ESG initiatives, the company updated its materiality matrix, set CO2 reduction targets aiming for SBT certification, and achieved 10.7% female managerial staff.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2018-2019
Period: 1 April 2018 – 31 March 2019
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services